At first glance, feathers may seem like simple parts of a bird’s body. But if you look closer—under a microscope or through a ...

The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang ...

For the past decade, Stealth BioTherapeutics has ridden a roller coaster trying to convince the Food and Drug Administration ... and nearly ending its development efforts, Stealth last October ...

NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (" 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.

KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• ...

Two unique job training centers in Hawaii are slated for closure in a Trump administration move to terminate the federal government’s 61-year-old Job Corps program. The U.S. Department of Labor ...

As AI transforms medicine, some of the most promising healthcare innovations are at risk of exclusion by Medicare’s outdated and complex ...

The Company’s expansion efforts come amid an increase in the global focus on scalable respiratory solutions, which may position the Company as a strtegic platform for public health initiatives and ...

Discover 8 hidden depression risk factors most people miss. Learn warning signs, genetic influences, and lifestyle triggers ...

“The first patient in Prescient’s Phase 2a study has been dosed at the Linear Clinical Research site in Perth, under the care ...